| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01394848 Details | 2013-12-04 Interventional | 4 | 1 | Atorvastatin Clopidogrel Everolimus Angina, Stable Stable Angina | Previous other study including EPC capture stent raised the issue of safety (significant high
incidence of instent restenosis) - | |||
| NCT00329537 Details | 2013-12-04 Interventional | 2 | 11 | Sargramostim Crohn Disease Crohn's Disease | - - | |||
| NCT00295165 NCT00295321 Details | 2013-12-04 Interventional | 3 | 33 | Sargramostim Crohn Disease | - - | |||
| NCT00206713 Details | 2013-12-04 Interventional | 3 | 264 | Sargramostim Crohn Disease | - - | |||
| NCT00206700 NCT00185471 Details | 2013-12-04 Interventional | 2 | 378 | Sargramostim Crohn Disease | - - | |||
| NCT00206661 Details | 2013-12-04 Interventional | 1/2 | 22 | Molgramostim Sargramostim Crohn Disease | - - | |||
| NCT01997203 Details | 2013-11-28 Interventional | 3 | 100 | Interferons Ribavirin Vitamin D Hepatitis Hepatitis A Hepatitis C Hepatitis C, Ch… Chronic Hepatit… | complete patients samples required - | |||
| NCT00350948 Details | 2013-11-27 Interventional | 3 | 244 | Doxorubicin Liposomal doxor… Ovarian Neoplas… | Business reasons - | |||
| NCT00216008 Details | 2013-11-25 Interventional | 2 | - | Docetaxel Adenocarcinoma Adenocarcinomas… Esophageal Aden… | IRB Closure - | |||
| NCT01269658 Details | 2013-11-21 Interventional | 2 | 40 | Azithromycin Ophthalmic Solu… Blepharitis | - - | |||
| NCT00199381 Details | 2013-11-21 Interventional | 3 | 504 | Istradefylline Parkinson Disea… Parkinson's Dis… | Additional long-term safety data no longer needed The Sponsor decided to terminate the study early (not for safety reasons); as a result 323 subjects discontinued early. Mean duration of therapy was 18.7 months (0.4 to 31.4 months); median duration was 21.0 months. Total exposure 767 subject years. | |||
| NCT01498406 Details | 2013-11-20 Interventional | 2 | 3 | Cholecalciferol Ergocalciferols Vitamin D Vitamins Lupus Erythemat… Cutaneous Lupus… | secondary to funding issues and low enrollment - | |||
| NCT00004159 Details | 2013-11-20 Interventional | 1/2 | 54 | Gemcitabine Paclitaxel Carcinoma, Non-… Lung Neoplasms Lung Cancer | - - | |||
| NCT01432106 Details | 2013-11-18 Interventional | 1 | 0 | Ramipril Valsartan Hypertension Metabolic Syndr… Syndrome | Novartis terminated all projects involving aliskiren. Findings of the DMC overseeing the
ALTITUDE clinical trial found a higher incidence of adverse events. - | |||
| NCT01214291 Details | 2013-11-15 Interventional | 3 | 0 | Toremifene Fractures, Bone Prostatic Neopl… Risk of Bone Fr… | cost of conducting the study and increased burden on the clinical trial professionals make it
impossible for us to proceed with the development of the drug. - | |||
| NCT01726465 Details | 2013-11-13 Interventional | 2 | 50 | Acetylcysteine Methylprednisol… Methylprednisol… Methylprednisol… N-monoacetylcys… Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… Hepatic Insuffi… Liver Failure Reperfusion Inj… Insufficiency; … Ischemic Reperf… Liver Tumour | The first phase was completed - | |||
| NCT00301886 Details | 2013-11-13 Interventional | 3 | 0 | Ibandronic Acid Zoledronic Acid Breast Neoplasm… Hypercalcemia Neoplasms Breast Cancer Hypercalcemia o… Metastatic Canc… Pain | withdrawn support for study - | |||
| NCT01628055 Details | 2013-11-11 Interventional | 1 | 0 | Antibodies Immunoglobulin … Immunoglobulins Immunoglobulins… Rho(D) Immune G… gamma-Globulins Cerebral Infarc… Ischemia Ischemic Stroke Stroke | difficult recruitment and new black box warning for IVIG - | |||
| NCT00308113 Details | 2013-11-08 Interventional | 3 | 3 | Coenzyme Q10 Prednisone Ubiquinone Muscular Dystro… Muscular Dystro… Duchenne Muscul… | New enrollment has been suspended, currently following previously enrolled participants In December 2007 the CINRG Data Safety and Monitoring Board (DSMB) met and recommended to close the study as the AAN had released practice parameters recommending that all patients with DMD should be offered treatment with corticosteroids. | |||
| NCT00095641 Details | 2013-11-08 Interventional | 2 | 0 | Capecitabine Carcinoma Carcinoma, Squa… Recurrence Squamous Cell C… Recurrent Squam… Recurrent Squam… Recurrent Squam… Recurrent Squam… Recurrent Squam… | no longer studying this disease site - |